GSK aims to shrink its consumer health PR roster; Merck accused of sunscreen overcharges; Bayer files for 4th Eylea use in EU;

> GlaxoSmithKline ($GSK) is reviewing its U.K. consumer health public relations accounts, aiming to cut down on the number of different agencies handling the products. Report

> Merck ($MRK) has been named in a proposed class-action suit claiming that the company overcharges for its Coppertone sunscreen products with SPFs of 55 and above, because they have "virtually identical" active ingredients as Coppertone products with a lower SPF. Report (reg. req.)

> Bayer asked European officials to approve a fourth indication for its injectable ophthalmology drug Eylea, as a treatment for visual impairment from macular edema caused by branch retinal vein occlusion. Report

> The physician drug compendium Epocrates topped the rankings of medical reference apps for smartphones for the fifth year in a row. Release

> AstraZeneca ($AZN) backed a series of videos to promote Mental Health America's latest awareness campaign. Report

> The FDA issued new guidance on distributing journal reprints, this time in relation to articles conveying new risk information. Report

> Sagent Pharmaceuticals made Crain's Chicago Business' list of fastest-growing companies in the region. Report

And Finally... AbbVie ($ABBV) unveiled results of a study of treatment adherence in patients with inflammatory disorders. Release

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.